Citations

Showing 10 of 108083 citations.

1244: CAN ADMINISTRATION OF HIGH-DOSE HYDROXOCOBALAMIN IMPROVE OUTCOMES IN REFRACTORY SEPTIC SHOCK?
Balasubramanian, Prasanth , Lewis, K.L. , Sahay, Aditya, Venegas, Carla , Mueller, Karl, Khosla, Atulya Aman

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 621-621

10.1097/01.ccm.0000910712.91031.b9 Get It

525: BLADDER ASSESSMENT AND MANAGEMENT IN ACUTE STROKE PATIENTS
Peacock, Sarah, Fouda, Eslam, Freeman, William D. , Porter, Steven B.

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 250-250

10.1097/01.ccm.0000907828.42132.bf Get It

524: ANALGESIC EFFICACY OF INTRAVENOUS KETAMINE IN GERIATRIC PATIENTS TREATED IN THE EMERGENCY DEPARTMENT
Beaudrie-Nunn, Aeryana, Wieruszewski, Erin D. , Woods, Emily , Canterbury, Elizabeth, Woods, Emily, Bellolio, Fernanda , Mara, Kristin C.

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 249-249

10.1097/01.ccm.0000907824.69373.8e Get It

573: FAMILY COMMUNICATION IN THE ICU: CHALLENGES AND SOLUTIONS
Karnatovskaia, Lioudmila V. , Ahmad, Sumera , Niven, Alexander S.

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 274-274

10.1097/01.ccm.0000908020.70389.3b Get It

515: SAFETY AND EFFECTIVENESS OF SODIUM ACETATE FOR INTRACRANIAL PRESSURE MANAGEMENT
Brown, Caitlin S. , Vollmer, Nicholas, Kooda, Kirstin , Braksick, Sherri A. , Mara, Kristin C. , Skrupky, Lee P. , Wijdicks, Eelco F. M. , Rabinstein, Alejandro A.

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 245-245

10.1097/01.ccm.0000907788.49390.36 Get It

568: HUMANIZING THE INTENSIVE CARE UNIT: PERSPECTIVES OF PATIENTS AND FAMILIES ON GET-TO-KNOW-ME BOARD
Ahmad, Sumera , Rhudy, Lori M. , Karnatovskaia, Lioudmila V. , Fogelson, Lindsay A., Gajić, Ognjen, LeMahieu, Allison , Barwise, Amelia , Gajic, Ognjen

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 272-272

10.1097/01.ccm.0000908000.34467.1a Get It

627. Too Much of a Good Thing? The Clinical Effects of Very High Serum Posaconazole Levels
Jannetto, Paul J. , Chesdachai, Supavit , Saleh, Omar Abu , Chesdachai, Supavit , Jensen, Kelsey , Mara, Kristin C. , Yetmar, Zachary A. , Rivera, Christina G.

Mayo Clinic

Open Forum Infectious Diseases | December 15, 2022 | Volume: 9 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofac492.679 Get It

Abstract Background Posaconazole therapeutic drug monitoring (TDM) is widely utilized to assess therapeutic efficacy and safety (i.e., hepatotoxicity, QTc prolongation); however, little is known about clinical effects of very high serum posaconazole serum levels (i.e., ≥ 5000 mg/mL). Reported incidence rate of adverse drug reactions (ADRs) with posaconazole per most recent clinical trial was ∼30%. The primary objective was to compare the ADR incidence in patients with serum posaconazole levels of 3000-4999 ng/mL to ≥5000 ng/mL. Methods This retrospective cohort study included adult patients with a posaconazole serum level ≥3000 ng/mL from 1/1/2019 to 04/30/2021. The primary outcome was symptomatic ADR at time of first serum level ≥3000 ng/mL. Secondary outcomes were laboratory defined hepatoxicity, electrolyte and adrenal laboratory abnormalities, QTc changes, and dose changes in response to TDM. Patient outcomes were censored after the first serum level and were compared between groups using Fisher’s exact tests. Results Ninety patients met inclusion criteria, 80 with a level of 3000-4999 ng/mL and 10 with a level of ≥ 5000 ng/mL occurring at a median of 91 days (26-443) and 27 days (12-45) from posaconazole initiation, respectively. Majority of patients were immunocompromised (55.6% transplant recipients, 28.9% active malignancy, 5.6% other) with a split of treatment (50%) and prophylaxis (42.2%) indication. Symptomatic ADRs were very common in patients with posaconazole levels of ≥5000 ng/mL and 3000-4999 ng/mL (80% vs. 58.8%; p=0.31), primarily neurologic (49.1% overall) followed by gastrointestinal (32.7% overall). Hepatotoxicity was also common (≥5000 ng/mL 40% vs 3000-4999 ng/mL 23.4%, p=0.26). Fifty percent of patients had the posaconazole dose continued without change. Electrolytes and QTc results were similar between groups, but median overall QTc was borderline high (456 [IQR 435, 479]). Conclusion There are safety concerns for patients with serum posaconazole levels ≥3000 ng/mL. Posaconazole levels should be monitored and, importantly, dose adjusted according to serum level and patient symptoms for both treatment and prophylaxis indications. Disclosures Christina G. Rivera, PharmD, Gilead: Grant/Research Support|Gilead: Honoraria|Insmed: Honoraria.
1159: UNANTICIPATED AIRWAY DECOMPENSATION AFTER A MINOR FALL
Grossman, Ashley Wong, Grossman, Daniel , McGuire, Sarayna S. , Grossman, Daniel

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 578-578

10.1097/01.ccm.0000910372.87023.0d Get It

1206: BETA-LACTAM DOSING IN PATIENTS WITH SEPSIS AND AKI: A MULTICENTER OBSERVATIONAL STUDY
King, Travis, Lemieux, Steven M., Lumpkin, Mollie, McCreary, Erin K , Ruggero, Michael , Heil, Emily L. , Thompson Bastin, Melissa L , Rech, Megan A. , Betthauser, Kevin D. , Heavner, Mojdeh S. , Horng, Michelle , Wieruszewski, Patrick M.

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 601-601

10.1097/01.ccm.0000910560.21924.72 Get It

1269. End HIV with DOT: Maybe?
Garcia, Bismarck Bisono, Bengualid, Victoria, Dahdouh, Michelle, Marinello, Carla, Salazar, Hernando, Berger, Judy, Salazar, Hernando

Mayo Clinic

Open Forum Infectious Diseases | December 15, 2022 | Volume: 9 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofac492.1100 Get It

Abstract Background Directly observed Therapy (DOT) has proven to be a valuable asset used in ascertaining adherence to tuberculosis (TB) medications, methadone, psychiatric medications and HIV medications. Both HIV and TB share the need of adherence to treatment to avoid resistance. However, unlike TB, HIV treatment must be taken for life. Argus Community (Argus DOT) provides Directly Observed Therapy to assist with medication adherence to HIV positive patients with medication adherence barriers who are not virally suppressed as long as the patient is from an affiliated medical provider network which includes St. Barnabas Designated AIDS Center (SBH DAC). Methods SBH DAC started referring patients who have not been virally suppressed to Argus DOT March 2021 to help reach our goal of 90% virally suppressed rate (viral load < 200 copies/ml) by the end of 2021. Those who agreed to DOT were referred, accepted and enrolled in Argus. Argus DOT calls patients daily Monday to Friday to remind them to take their medications. We performed a retrospective chart review of SBH DAC/Argus DOT patients to see if this intervention improved our suppression rate from March 2021 to December 2021 and if there were any barriers for our patients in regards to receiving these benefits. Results 18 patients were approached by the DAC team to enroll in Argus DOT; of those 15 originally agreed to the program. 3 patients declined the enrollment. Of the 15 patients who agreed to the program, 6 patients discontinued the program and none of these 6 patients achieved viral load suppression. Results of 9 patients who stayed with Argus DOT: 8 out of 9 patients achieved a viral load < 200 copies/ml and one achieved 230 copies/ml from 2200 copies/ml. 2 patients achieve a viral load < 20 copies/ml (undetectable). Conclusion This small study shows Argus DOT as valuable asset in achieving decrease HIV viral load in patients with medication adherence barriers. 50% accepting and staying with the program achieved 89% viral suppression; close to the 90% needed to End the Epidemic. 9 out of 18 who did not agree or discontinued Argus DOT due to uncontrolled psychiatric, substance use, nonworking phones and distrust did not achieve viral suppression. Co-located psychiatric, substance use as well as in-house SBH DOT personnel is needed to achieve viral load suppression. Disclosures All Authors: No reported disclosures.